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Picomolar inhibition of cholera toxin by a pentavalent
ganglioside GM1os-calix[5]arene†
Jaime Garcia-Hartjes,‡a Silvia Bernardi,‡b Carel A. G. M. Weijers,a Tom Wennekes,a
Michel Gilbert,c Francesco Sansone,b Alessandro Casnati*b and Han Zuilhof*a,d
Cholera toxin (CT), the causative agent of cholera, displays a pentavalent binding domain that targets the
oligosaccharide of ganglioside GM1 (GM1os) on the periphery of human abdominal epithelial cells.
Here, we report the ﬁrst GM1os-based CT inhibitor that matches the valency of the CT binding domain
(CTB). This pentavalent inhibitor contains ﬁve GM1os moieties linked to a calix[5]arene scaﬀold. When
evaluated by an inhibition assay, it achieved a picomolar inhibition potency (IC50 = 450 pM) for CTB. This
represents a signiﬁcant multivalency eﬀect, with a relative inhibitory potency of 100 000 compared to a
monovalent GM1os derivative, making GM1os-calix[5]arene one of the most potent known CTB
inhibitors.
Introduction
Cholera still represents a serious health problem in areas of
the developing world where there is a lack of clean water and
proper sanitation. In 2012, the World Health Organization esti-
mated that annually 3–5 million cholera cases occur that result
in more than 100 000 deaths.1 Although several treatments
exist for cholera,2 resistance development and mutations in
the causative pathogen mean that eﬀorts made to better
understand the disease pathogenesis and develop new treat-
ments are crucial.3,4 The symptoms of cholera are caused by
cholera toxin (CT), which is produced by the Vibrio cholerae
bacterium. CT is a member of the AB5 toxin family that con-
tains a pentameric binding domain (CTB) for recognition and
binding to cell surfaces.5 The natural target ligand for CTB is
the glycosphingolipid ganglioside GM1, on cellular mem-
branes of the infected hosts’ intestinal epithelial surface. CTB
can bind five GM1 saccharide epitopes simultaneously with
the terminal Gal- and the Neu5Ac carbohydrate units of the
ganglioside as the major contributors to the binding.6,7
The adhesion of CTB to ganglioside GM1 on cell surfaces is the
prerequisite for endocytosis of the toxic enzymatically active A
subunit of CT, and the ensuing severe clinical symptoms.8 One
avenue in cholera research is to study the binding of CTB to
GM1 and to develop CTB inhibitors that might prevent CT
from binding the hosts’ cell surface and thereby also the deve-
lopment of cholera. Here, we present the second of two
examples of a pentavalent GM1os-based inhibitor for CTB,
GM1os-calix[5]arene (1; Fig. 1). In the previous paper in this
issue, we also reported on pentavalent inhibitors of CTB based
on a GM1os-presenting corannulene scaﬀold. In the past,
several studies have focused on the development of multi-
valent glycosylated inhibitors for CTB based on ganglioside
GM1.9 It is noteworthy that in none of these studies, inhibitors
were investigated with a pentavalent structure that matches the
pentavalent structure of CTB. On the other hand, pentavalent
Fig. 1 Developed CTB inhibitor: penta-GM1os-calix[5]arene (1).
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cyclens10,11 and cyclic peptides12 have been described as CTB
inhibitors, but those contained only the much simpler galac-
tose epitope likely to get around the diﬃculty to obtain
suﬃcient tailor-made GM1os. Therefore, also GM1 mimics
have been used, e.g. Thompson and Schengrund described
poly(propylene) imine dendrimers that present the Galβ1–
3GalNAcβ1–4(Neu5Acα2–3)Galβ-epitope of GM1,13 with IC50
values for the tetravalent and octavalent dendrimers of 7 and
3 nM, respectively. Bernardi et al. published a series of GM1-
mimics (pseudo-GM1), in which the residues in the GM1os
that are not essential for binding were replaced by a confor-
mationally restricted cyclohexane-diol and the Neu5Ac-unit
was substituted by various α-hydroxy acids.14,15 When attached
to multivalent dendritic structures,16 the relative inhibitory
potency (RIP) values per mimic unit of the tetravalent and
octavalent inhibitors were 111 and 55, respectively. Interest-
ingly, when the same mimic was linked to a divalent calix[4]-
arene scaﬀold,17 a 4000-fold enhancement in binding eﬃciency
was achieved compared to the monovalent pseudo-GM1. These
data suggested to us that the calixarene macrocycle, from
which the binding inhibitors are projected, could be a promis-
ing multivalent scaﬀold18–20 to design CTB inhibitors with
improved eﬃciency. In collaboration with the group of Pieters,
we previously published divalent, tetravalent, and octavalent
dendritic structures decorated with GM1os.21,22 For the octa-
valent compound the unprecedentedly low IC50 value of 50 pM
was observed with an RIP of 17 500 per arm compared to its
monovalent counterpart. However, its mismatched valency
compared to CTB prompted us to investigate a pentavalent
scaﬀold as core structure that when decorated with GM1os
has the potential to form 1 : 1 inhibitor–CTB complexes.
The current paper presents the convergent synthesis of the
first, water-soluble, pentavalent CTB inhibitor (1), which
was made by coupling five GM1os units to a calix[5]arene
scaﬀold.
Results and discussion
We designed a 5-fold symmetric calix[5]arene as a pentavalent
scaﬀold structure. This calix[5]arene (Fig. 1) presents small
methoxy groups at the lower rim, which confer a high confor-
mational flexibility to the macrocyclic structure.23 The upper
rim of the calixarene inhibitor is decorated with the GM1 penta-
saccharide separated from the macrocyclic core by appropriate
linkers. Fan and coworkers12 have demonstrated that an
optimal linker length is vital for the potency of a synthetic
multivalent inhibitor. For the calix[5]arene, described here, a
31 atom-containing linker was chosen. This should allow the
simultaneous interaction of the five GM1os units with the five
B-subunits of a single toxin.5
The route towards our target (1) started with the synthesis
of the pentavalent scaﬀold that began with the preparation of
the known p-tert-butyl-calix[5]arene.24 This product was con-
verted into p-H-calix[5]arene 225 by following literature pro-
cedures. Next, penta-aldehyde 3 was obtained in 57% yield
from 2 by exploiting the Duﬀ formylation reaction.26,27 Com-
pound 3 was subsequently methylated at the lower rim by
using CH3I and K2CO3 in acetonitrile aﬀording the penta-
methoxy-calix[5]arene 4 in 68% yield (Scheme 1).
Oxidation of 4 with NaClO2 and NH2SO3H produced the
penta-carboxylic acid 5. The unsymmetrically substituted
azido-penta-(ethyleneglycol)-amine 7 was synthesized from
hexa-ethylene glycol by ditosylation, substitution to the diazide,
and finally selective Staudinger reduction of one azide.28,29
Initial attempts to condense amine 7 with the carboxylic acids
Scheme 1 Synthesis of the penta-azido-calix[5]arene (8) scaﬀold. Reagents and conditions: (a) HMTA, CF3COOH, reﬂux, N2, 5 days, 57%; (b) CH3I, K2CO3 CH3CN,
reﬂux, N2, 20 h, 68%; (c) NaClO2, NH2SO3H, (CH3)2CO, CHCl3, H2O, rt, 24 h, 79%; (d) (COCl)2, dry CH2Cl2, N2, rt, 18 h, quant.; (e) Et3N, dry CH2Cl2, N2, rt, 20 h, 44%.
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in 5 using HBTU resulted in diﬃcult purification and low
yields (∼20%) of 8. However, when this spacer (7) was attached
to calix[5]arene 5 via penta-acyl chloride intermediate 6 it pro-
vided penta-azido-calix[5]arene 8 in a 44% yield.
With the calix[5]arene (8) scaﬀold in hand we proceeded to
the next stage, attaching five GM1 oligosaccharides. We chose
the copper-catalyzed azide–alkyne cycloaddition (CuAAC) reac-
tion to achieve this, which meant a GM1os derivative with a
terminal alkyne was required. This C11-alkyne-terminated
GM1os 9 (Scheme 2) was made via a chemo-enzymatic
procedure previously reported by us,30 which allowed the
production of 9 on gram scale. Compound 9 was subsequently
“clicked” to scaﬀold 8 under standard CuAAC conditions in
H2O while exposed to microwave irradiation to successfully
provide our crude target inhibitor 1. With our target penta-
valent GM1os-calix[5]arene 1 in hand, in order to properly assess
the role of the GM1os in inhibitor 1, we also set out to syn-
thesize derivatives of 1 containing fragments of the GM1os to
use for comparison in the biological assays. The first of these
was penta-GM2os-calix[5]arene (11) that lacks the terminal
galactose epitope compared to the GM1os. We synthesized 11
using the same CuAAC reaction conditions from scaﬀold 8 and
Scheme 2 Synthesis of GM1os-calix[5]arene (1) and GM2os-calix[5]arene (11); (a) CuSO4·5H2O, sodium ascorbate, Triton X-100, CH3OH, H2O, MW (150 W), 80 °C,
1 h; 51% 1, 59% 11.
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a chemo-enzymatically produced alkyne-terminated C11-linked
GM2os sugar (10).
With both our target 1 and its derivative 11 in hand as
crude products, we investigated what purification method
would be suitable for these large complex molecules. An initial
purification by size exclusion chromatography (SEC) eﬃciently
removed an excess of alkyne-terminated GM1os 9 and GM2os
10, respectively. However, the crude products both also con-
tained a minor amount of tetravalent byproducts as could be
clearly seen with mass spectrometry and their separation
proved to be quite challenging. Initial attempts to separate
these by aqueous HPLC GPC failed, but after extensive opti-
mization, reversed phase HPLC purification proved the most suc-
cessful for this final purification step (see experimental
section for details). Fig. 2 shows a typical HPLC chromatogram
for the separation of both the GM1os- and GM2os-calix[5]-
arenes. Despite attempts to improve the moderate resolution,
the purification remained quite complicated because of long
elution times (up to 40 minutes per run) and high aﬃnity of
the products with the column material. Collection of small
fractions in a specific retention time window over multiple
HPLC injections and subsequent lyophilization resulted
indeed in pure pentavalent GM1os- and GM2os-calix[5]arenes
(1 and 11) as shown by HR-MS and NMR analyses. The other
impure fractions that also contained 1 or 11 were collected,
pooled, lyophilized and re-injected to achieve optimal yields.
Attempts were made to isolate the tetravalent byproducts, but
insuﬃcient amounts could be obtained for further analyses.
Besides the GM2os containing calixarene (11), we also pre-
pared two further derivatives of 1 that contained fragments of
GM1os, a pentavalent β-galactoside- (16) and β-lactoside-calix-
[5]arene (17) (Scheme 3). These more simple carbohydrates
enabled a modified synthesis procedure that circumvented the
potentially challenging HPLC purification, as encountered for
compounds 1 and 11. The coupling was also performed by
employing the microwave-assisted CuAAC reaction on penta-
azido-calixarene scaﬀold 8, but instead of using the depro-
tected carbohydrates, acetyl-protected galactoside 12, and lacto-
side 13 were reacted. The resulting products could now be
purified by normal phase silica gel chromatograpy. The acetyl-
protected 14 and 15 were deprotected by employing standard
Zemplén31 conditions to obtain galactoside-calix[5]arene 16,
and lactoside-calix[5]arene 17, respectively, which did not
require further purification after work-up.
Finally, in order to properly determine the multivalency
eﬀect of the interaction of 1 with CTB in our biological assays,
we also synthesized the monovalent GM1os derivative 20
(Scheme 4). This was achieved by first in situ generation of the
acyl chloride of commercially available 4-methoxybenzoic acid
with oxalyl chloride and, subsequently, reacting this with
amino-azide 7, yielding azide 19 in 20% over two steps. Again,
by employing the microwave-assisted CuAAC reaction on
alkyne-terminated 9 and azide 19, GM1os-monomer 20 was
obtained in a reasonable yield (49%).
The inhibitory potency of the four pentavalent compounds
(1, 11, 16, and 17) was determined by ELISA experiments. In
the assays, the ability of 1, 11, 16 and 17 to inhibit the binding
of HRP-labeled CTB was measured in competition with the
natural ligand ganglioside GM1, which was adsorbed to the
well surface of the ELISA plate. GM1os-calix[5]arene 1 showed
a high inhibition potency, i.e., a very low IC50 value of 450 pM
(Fig. 3, Table 1). Comparing the IC50 value (44 μM) of the
monovalent control compound (20) to that of 1 revealed a 100-
thousand increase in inhibitory potency, and an RIP of 20-
thousand per arm. Pentavalent inhibitors based on a more
rigid corannulene scaﬀold, which we also report in this issue,
inhibited CTB in the nanomolar range.32 Assay results for the
GM2os-calix[5]arene 11 confirmed the importance of using
GM1os. Lacking only the terminal galactose compared to 1, it
produced an IC50 of 9 μM, which is 20-thousand fold worse
compared to 1. The galactose-terminated (16) and lactose-ter-
minated (17) calix[5]arenes displayed a higher inhibition con-
centration than their solubility in the assay medium, and their
IC50 could therefore only be determined as being >1 mM
(Table 1).
Conclusions
In summary, we here report the synthesis and initial biological
evaluation of the first known example of a pentavalent GM1os-
based inhibitor of cholera toxin that matches the valency of
the cholera toxin B-subunit. With an IC50 of 450 pM, the penta-
valent GM1os-calix[5]arene (1) also displays the highest relative
inhibitory potency, 20-thousand per arm (compared to 20),
documented thus far for CT inhibitors. We are currently using
the here reported convergent synthetic route to further explore
the structure–activity-relationship of 1 and improve its
potency. Among other issues we are interested in investigating
the eﬀect of the length, rigidity and hydrophobicity of the used
spacer and restricting the flexibility of the calix[5]arene
scaﬀold to a fixed cone structure.
Fig. 2 LCMS trace of the puriﬁcation of GM2-calix[5]arene 11. (left) Chromato-
gram of the puriﬁcation on a reversed phase column (see experimental section
for details). (right) Mass spectra for two fractions, the pentavalent product 11 at
RT = 12 min, and the tetravalent byproduct at 21 min.
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Experimental section
General experimental information
All moisture sensitive reactions were carried out under a nitro-
gen atmosphere, using previously oven-dried glassware. All dry
solvents were prepared according to standard procedures, dis-
tilled before use and stored over 3 Å or 4 Å molecular sieves.
Reagents were obtained from commercial sources and used
without further purification unless stated otherwise. Analytical
TLC was performed using prepared plates of silica gel (Merck
60 F-254 on aluminium) and then, according to the functional
groups present on the molecules, revealed with UV light or
using staining reagents: FeCl3 (1% in H2O–CH3OH 1 : 1),
H2SO4 (5% in EtOH), ninhydrin (5% in EtOH), basic solution
of KMnO4 (0.75% in H2O). Merck silica gel 60 (70–230 mesh)
was used for flash chromatography and for preparative TLC
plates. 1H NMR and 13C NMR spectra were recorded on Bruker
AV300, Bruker AV400, Bruker DPX400, and Bruker AV600
equipped with cryoprobe spectrometers (observation of 1H
nucleus at 300 MHz, 400 MHz, 600 MHz, respectively, and of
13C nucleus at 75 MHz, 100 MHz, and 151 MHz, respectively).
Chemical shifts are reported in parts per million (ppm), cali-
brated on the residual peak of the solvent, whose values are
referred to tetramethylsilane (TMS, δTMS = 0), as the internal
Scheme 3 Synthesis of galactoside-calix[5]arene (16), and lactoside-calix[5]arene (17); (a) CuSO4·5H2O, sodium ascorbate, DMF, H2O, MW (150 W), 80 °C, 1 h;
67% 14, 57% 15; (b) NaOMe–MeOH, 4 h – 18 h, H+-resin; 90% 16, 72% 17.
Scheme 4 Synthesis of GM1-monomer 20; (a) (COCl)2, dry CH2Cl2, N2, rt, 18 h; (b) 7, Et3N, dry CH2Cl2, N2, rt, 20 h; 20% in two steps; (c) 9, CuSO4·5H2O, sodium
ascorbate, Triton X-100, CH3OH, H2O, MW (150 W), 80 °C, 1 h; 49% 20.
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standard. 13C NMR spectra were performed with proton decou-
pling. Electrospray ionization (ESI) mass analyses were per-
formed with a Waters spectrometer, while high resolution ESI
mass analyses were recorded on a Thermo Scientific Q Exactive
spectrometer. Melting points were determined on an Electro-
thermal apparatus in closed capillaries. Microwave reactions
were performed on a CEM Discovery System reactor running
on Discover Application Chemdriver Software v3.6.0. HPLC
was performed on an HP 1100 series with a DAP 190–600 nM
detector, equipped with a Waters Xterra 100 × 4.6 mm C18
column eluted with isocratic iPrOH–H2O 35 : 65, and a flow of
0.4 mL min−1, unless stated otherwise. Materials for the ELISA
experiments i.e. bovine serum albumin (BSA), bovine brain
GM1, ortho-phenylenediamine (dihydrochloride salt) (OPD),
cholera toxin horseradish peroxide (CTB-HRP) conjugate,
Tween-20, 30% H2O2 solution, sodium citrate, and citric acid
were purchased at Sigma Aldrich and used without further
modification, phosphate-buﬀered saline (PBS) 10× concentrate
was diluted ten times with demineralized water prior to use.
Nunc F96 MaxisorpTM 96-well microtiter plates were used as
purchased at Thermo Scientific. The microtiter plates were
washed using an automated Denville® 2 Microplate Washer.
Optical density (OD) was measured between 1.5 and 0.5 units
on a Thermo Labsystems Multiskan Spectrum Reader running
on Skanit software version 2.4.2. Data analysis and curve
fitting of inhibition experiments were performed on Prism
Graphpad software v5.04. Simplified nomenclature proposed
by Gutsche33 is used to name the calix[5]arene compounds.
Compounds 31,32,33,34,35-pentahydroxycalix[5]arene 2,25
17-azide-3,6,9,12,15-pentaoxaheptadecane-1-amine 7,29 undec-
10-ynyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 12,30 undec-
10-ynyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-2,3,6-
tri-O-acetyl-β-D-glucopyranoside 1330 were prepared according
to literature procedures.
GM1-calix[5]arene (1)
Calix[5]arene 8 (15.7 mg, 6.93 μmol) was dissolved in 0.5 mL
of CH3OH in a microwave tube. Then the GM1os derivative 9
(59.8 mg, 52.1 μmol), previously synthesized by chemo-enzy-
matic procedures,30,34 was combined with CuSO4·5H2O
(0.52 mg, 2.1 μmol), sodium ascorbate (0.82 mg, 4.2 μmol),
4 mL of H2O and a drop of Triton X-100. The mixture was
heated at 80 °C by microwave irradiation (150 W) for 60 min.
The reaction progression was monitored via TLC (eluent:
AcOEt–CH3OH–H2O–AcOH 4 : 2 : 1 : 0.1) and ESI-MS analyses.
The crude mixture was purified via size exclusion column
chromatography (Sephadex G-15, eluent: H2O 100%) and
HPLC purification (see General information) giving product 1
as a white solid. Yield: 51%. 1H NMR (600 MHz, D2O): δ (ppm)
7.61 (s, 5H, H5 triazole); 7.50 (s, 10H, Ar); 4.69 (bs, 5H, H1-
GalNAc); 4.43 (d, 5H, J = 8.0 Hz, H1-Gal′); 4.44–4.41 (m, 5H,
H1-Gal); 4.38–4.37 (m, 5H); 4.32–4.31 (5H, d, J = 7.9 Hz, H1-
Glc); 4.05–4.02 (m, 15H); 3.94–3.92 (m, 5H, H2-GalNAc);
3.86–3.60 (m, 105H); 3.60–3.45 (m, 80H); 3.46–3.33 (m, 75H);
3.26–3.24 (m, 5H, H2-Gal); 3.18–3.15 (m, 5H, H2-Glc); 3.10 (bs,
10H); 2.56–2.54 (m, 5H, H3a-Neu5Ac); 2.45–2.42 (m, 10H, tria-
zole-CH2CH2CH2); 1.92 (s, 15H, NC(O)CH3-Neu5Ac); 1.89 (s,
15H, NC(O)CH3-GalNAc); 1.85–1.80 (m, 5H, H3b-Neu5Ac);
1.44–1.35 (m, 20H, CH2 aliphatic chain); 1.14–1.08 (m, 10H,
CH2CH2OC1-Glc), 1.03 (m, 40H, CH2 aliphatic chain).
13C
NMR (151 MHz, D2O): δ (ppm) 175.4, 175.1, 174.5 (C(O)); 169.1
(ArC(O)NH); 159.7 (Ar-ipso); 134.8 (Ar-ortho); 129.2 (Ar-para);
128.9 (Ar-meta); 123.7 (C5 triazole); 105.1 (C1-Gal′); 103.0 (C1-
Gal); 102.8 (C1-GalNAc); 102.5 (C1-Glc); 102.0 (C2-Neu5Ac);
80.7 (C3-GalNAc); 79.0 (C4-Glc); 77.6 (C4-Gal); 75.2 (C5-Gal′);
75.1 (C5-Glc); 74.9 (C3-Gal); 74.7; 74.4 (C5-Gal); 73.4 (C6-
Neu5Ac); 73.1 (C2-Glc); 72.8 (C3-Gal′); 72.6 (C7-Neu5Ac); 71.0
(C2-Gal′); 70.9 (β-COCH2); 70.4 (C2-Gal); 70.1–69.8; 69.4; 69.2;
69.0; 68.9; 68.4; 68.3 (C4-GalNAc); 63.1; 61.4; 61.3; 60.9; 60.5;
52.0; 51.5 (C2-GalNAc); 50.3; 40.0; 37.2; 31.1 (ArCH2Ar); 29.3,
29.1, 29.0, 28.9, 28.8 (CH2 aliphatic chain); 25.6 (CH2CH2OC1-
Glc); 25.0 (triazole-CH2CH2CH2); 23.0 (NHC(O)CH3-GalNAc);
22.4 (NHC(O)CH3-Neu5Ac). HR-ESI-MS(−): m/z 1600.5013
[100% (M − 5H)5−] calcd: 1600.7112.
5,11,17,23,29-Pentaformyl-31,32,33,34,35-pentahydroxycalix[5]-
arene (3)
Calix[5]arene 225 (0.41 g, 0.78 mmol) was added to a solution
of HMTA (2.5 g, 17.8 mmol) in 50 mL TFA and the mixture was
refluxed for 5 days under N2. The solvent was then removed
under reduced pressure and the residue dissolved in 12 mL of
a 1 : 1 CH2Cl2–HCl 1 M solution. The mixture was stirred at
room temperature for 24 h. The aqueous phase was extracted
Fig. 3 GM1os-calix[5]arene GM2os-calix[5]arene GM1os-monomer;
Fitted curves of the experimental ELISA inhibition data. For details of the inhi-
bition assays see experimental section.
Table 1 CTB inhibition potency for reported compounds
Entry Saccharide Valency # IC50
1 GM1os 5 1 450 pM
2 GM1os 1 20 44 μM
3 GM2os 5 11 9 μM
4 Galactose 5 16 >1 mM
5 Lactose 5 17 >1 mM
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with CH2Cl2 (5 × 5 mL). The combined organic phases were
washed with water (2 × 10 mL), dried over anhydrous Na2SO4,
filtered and the solvent removed under vacuum. The residue
was purified by trituration in CHCl3–hexane 1 : 1 to give the
product 3 as a brownish solid. Yield: 57%. 1H NMR (300 MHz,
CDCl3–CD3OD 9 : 1): δ (ppm) 9.75 (s, 5H, CHO); 7.70 (s, 5H,
ArOH); 7.22 (s, 10H, ArH); 3.45 (s, 10H, ArCH2Ar).
13C NMR
(75 MHz, CDCl3–CD3OD 9 : 1): δ (ppm) 192.1 (CHO); 150.6 (Ar-
ipso); 131.9 (Ar-para); 128.1 (Ar-meta); 127.2 (Ar-ortho); 31.4
(ArCH2Ar). HR-ESI-MS(+): m/z 671.1921 [100% (M + H)
+] calcd:
671.1917. M.p. > 300 °C.
5,11,17,23,29-Pentaformyl-31,32,33,34,35-pentamethoxy-calix-
[5]arene (4)
In a two-neck round-bottomed flask, pentaformylcalix[5]arene
3 (0.7 g, 1.1 mmol) was dissolved in 150 mL of dry CH3CN,
then K2CO3 (4.5 g, 32 mmol) and CH3I (2 mL, 32 mmol) were
added and the mixture was refluxed for 20 h under a nitrogen
atmosphere. The solvent was removed under reduced pressure
and the residue dissolved in 150 mL of a 1 : 1 solution CH2Cl2–
HCl 1 M. The mixture was stirred for 2 h at room temperature.
The organic layer was separated, and the aqueous phase
extracted with CH2Cl2 (2 × 50 mL). The combined organic
phases were washed with water (2 × 100 mL), dried over an-
hydrous Na2SO4, filtered and the solvent removed under reduced
pressure. The product 4 was obtained as a brown solid.
Yield: 68%. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.72 (s, 5H,
CHO); 7.50 (s, 10H, ArH); 3.92 (s, 10H, ArCH2Ar); 3.25 (s, 15H,
OCH3).
13C NMR (75 MHz, CDCl3–CD3OD 9 : 1): δ (ppm)
191.4 (CHO); 161.8 (Ar-ipso); 134.8 (Ar-para); 132.0 (Ar-ortho);
130.8 (Ar-meta); 60.6 (OCH3); 30.7 (ArCH2Ar). HR-ESI-MS(+):
m/z 741.2700 [100% (M + H)+] calcd: 741.2700. M.p.:
217–219 °C.
5,11,17,23,29-Pentacarboxy-31,32,33,34,35-pentamethoxycalix-
[5]arene (5)
Pentaformyl-pentamethoxycalix[5]arene 4 (0.25 g, 0.34 mmol)
was dissolved in a two-neck round-bottomed flask in 100 mL
of a mixture acetone–CHCl3 1 : 1, and cooled to 0 °C with an
ice-water bath. In another flask, a solution of NaClO2 80%
pure (0.47 g, 4.20 mmol) was dissolved in the minimum
amount of water. Subsequently, sulfamic acid (0.49 mg,
5.04 mmol) was added. This solution was slowly poured into
the reaction flask. The mixture was stirred at 0 °C for 15 min
and gradually warmed to room temperature while it remained
stirred for 24 h. The solvent was then removed under reduced
pressure and the residue triturated with 1 M HCl. After fil-
tration on a Büchner funnel, product 5 was obtained as a
solid. Yield: 79%. 1H NMR (300 MHz, CD3OD): δ (ppm) 7.75 (s,
10H, ArH); 3.93 (s, 10H, ArCH2Ar); 3.30 (s, 15H, OCH3).
13C
NMR (25 MHz, CD3OD): δ (ppm) 169.6 (CO); 162.1 (Ar-ipso);
135.8 (Ar-ortho); 132.0 (Ar-meta); 126.8 (Ar-para); 61.3 (–OCH3);
31.9 (ArCH2Ar). HR-ESI-MS(+): m/z 843.2269 [100% (M + Na)
+]
calcd: 843.2265.
5,11,17,23,29-Pentakis[(17-azide-3,6,9,12,15-pentaoxahepta-
decane-1-amino)carbonyl]-31,32,33,34,35-pentamethoxy-calix-
[5]arene (8)
In a round-bottomed flask, 0.12 g of calix[5]arene 5
(0.14 mmol) and 0.51 mL of oxalyl chloride (5.82 mmol) were
solubilized in 15 mL of dry CH2Cl2 under a nitrogen atmos-
phere. The solution was stirred for 18 h at room temperature
and then the solvent evaporated to dryness. The residual com-
pound 6 was dissolved again in 5 mL of dry CH2Cl2 and then
added dropwise to a solution of amine compound 7 (0.29 g,
0.87 mmol) and NEt3 (0.12 mL, 0.87 mmol) in 5 mL of dry
CH2Cl2. The mixture was stirred for 20 h at room temperature
under a nitrogen atmosphere. The mixture was then washed
with 1 M HCl, an aqueous solution of Na2CO3 and water till
neutral pH was reached. The solvent was removed under
vacuum and the crude purified by flash chromatography
(eluent: CHCl3–CH3OH 95 : 5) to give the product 8 as a yellow
oil. Yield: 44%. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.50 (s,
10H, ArH); 7.07 (bs, 5H, CONH); 3.89 (s, 10H, ArCH2Ar);
3.65–3.50 (m, 110H, OCH2, CH2NHCO); 3.34 (t, 10H, J = 4.8
Hz, CH2N3); 3.28 (s, 15H, OCH3).
13C NMR (100 MHz, CDCl3):
δ (ppm) 167.3 (CO); 159.2 (Ar-ipso); 134.2 (Ar-para); 129.8 (Ar-
ortho); 128.2 (Ar-meta); 70.6, 70.5, 70.2, 70.0, (OCH2); 60.8
(OCH3); 50.6 (CH2N3); 39.7 (CH2NHCO); 30.9 (ArCH2Ar).
HR-ESI-MS(+): m/z 1131.5698 [100% (M + 2H)2+]; calcd: 1131.5756.
GM2-calix[5]arene (11)
Calix[5]arene 8 (15.7 mg, 6.93 μmol) was dissolved in 0.5 mL
of CH3OH in a microwave tube. Then the GM2os derivative 10
(50.5 mg, 52.1 μmol), previously synthesized by chemo-enzy-
matic procedures,30,34 was added together with samples of
CuSO4·5H2O (0.52 mg, 2.1 μmol), sodium ascorbate (0.82 mg,
4.2 μmol), 4 mL of H2O and a drop of Triton X-100. The
mixture was heated at 80 °C by microwave irradiation (150 W)
for 60 min. The reaction progress was monitored via TLC
(eluent: AcOEt–CH3OH–H2O–AcOH 4 : 2 : 1 : 0.1) and ESI-MS
analyses. The crude material was purified via size exclusion
column chromatography (Sephadex G-15, eluent: H2O 100%),
followed by HPLC purification (see General information)
giving pure product 11 as a white solid. Yield: 59%. 1H NMR
(400 MHz, D2O/CD3OD): δ (ppm) 7.65 (s, 5H, H5 triazole); 7.54
(s, 10H, ArH); 4.70 (m, 5H, H1-Gal (determined by HSQC));
4.47–4.42 (m, 15H, H1-GalNAc); 4.36–4.35 (d, 5H, J = 7.6 Hz,
H1-Glc); 4.08–4.06 (m, 10H); 3.89–3.66 (m, 95H, ArCH2Ar);
3.58–3.43 (m, 150H); 3.32–3.30 (m, 5H, H2-Gal); 3.23–3.19 (m,
5H, H2-Glc); 3.14 (bs, 10H); 2.61–2.58 (m, 5H, H3a-Neu5Ac);
2.48 (bs, 10H); 1.97 (s, 15H, NHC(O)CH3-Neu5Ac); 1.95 (s, 15H,
NHC(O)CH3-GalNAc); 1.89–1.84 (m, 5H, H3b-Neu5Ac);
1.51–1.36 (bs, 20H, CH2 aliphatic chain); 1.23–0.95 (50H, m,
CH2 aliphatic chain). HR-ESI-MS(−): m/z 1440.4670 [100%
(M − 5H)5−] calcd: 1438.6588.
Peracetylated-galactosylcalix[5]arene (14)
Calix[5]arene 8 (32.0 mg, 14.1 μmol) and the β-galactoside
derivative 12 (52.9 mg, 106 μmol) were dissolved in 2.5 mL of
DMF in a microwave tube. CuSO4·5H2O (2.0 mg, 8.5 μmol),
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sodium ascorbate (3.3 mg, 16.9 μmol) and 0.5 mL H2O were
then added. The mixture was heated at 80 °C by microwave
irradiation (150 W) for 60 min. When the reaction was com-
pleted (checked via TLC, eluent: CH2Cl2–CH3OH 20 : 1), it was
quenched by addition of water (15 mL) and extracted with
AcOEt (5 × 15 mL). The combined organic layers were dried
over anhydrous Na2SO4, filtered and the solvent removed
under vacuum. The crude material was purified on preparative
TLC plates (eluent: CH2Cl2–CH3OH 9 : 1) giving product 14 as
a yellow oil. Yield: 67%. 1H NMR (300 MHz, CD3OD): δ (ppm)
8.21 (bs, 5H, C(O)NH); 7.77 (s, 5H, H5 triazole); 7.61 (bs, 10H,
ArH); 5.38 (d, 5H, J = 2.7 Hz, H4); 5.16–5.02 (m, 10H, H3, H2);
4.61 (d, 5H, J = 7.3 Hz, H1); 4.51 (t, 10H, J = 5.0 Hz, OCH2CH2-
triazole); 4.20–4.05 (m, 15H, H5, H6a, H6b); 3.94 (bs, 10H,
ArCH2Ar); 3.88–3.77 (m, 15H, OCH2CH2-triazole, β-COCHa);
3.70–3.44 (m, 105H, OCH2, β-COCHb, C(O)NHCH2); 3.29 (s,
15H, ArOCH3); 2.67 (t, 10H, J = 7.6 Hz, triazole-CH2CH2CH2);
2.13 (s, 15H, Ac); 2.02 (s, 15H, Ac); 2.01 (s, 15H, Ac); 1.94 (s,
15H, Ac); 1.71–1.59 (m, 10H, triazole-CH2CH2CH2), 1.59–1.47
(m, 10H, β-COCH2CH2), 1.40–1.23 (m, 50H, CH2 aliphatic
chain). 13C NMR (75 MHz, CD3OD) δ ppm: 172.0, 171.5, 171.2
(Ac); 169.6 (C(O)NH); 160.9 (Ar-ipso); 149.0 (C4 triazole); 135.8
(Ar-ortho); 130.7 (Ar-para); 129.7 (Ar-meta); 123.9 (C5 triazole);
102.2 (C1); 72.4 (C3); 71.7 (C5); 71.5, 71.4, 71.3, 70.9 (OCH2);
70.6 (OCH2CH2-triazole); 70.5 (C2); 68.8 (C4); 62.6 (C6); 61.5
(ArOCH3); 51.3 (OCH2CH2-triazole); 41.0 (C(O)NHCH2); 32.0
(ArCH2Ar); 30.6, 30.4, 30.2 (CH2 aliphatic chain); 27.0 (triazole-
CH2CH2CH2); 26.3 (CH2 aliphatic chain); 20.8, 20.6, 20.5
(CH3C(O)). HR-ESI-MS(+): m/z 1607.7872 [100% (M + 3Na)
3+]
calcd: 1607.7813.
Peracetylated-lactosylcalix[5]arene (15)
Calix[5]arene 8 (27.5 mg, 12.0 μmol) and the β-lactoside com-
pound 13 (70.0 mg, 89.0 μmol) were dissolved in 2.5 mL DMF
in a microwave tube. CuSO4·5H2O (2.6 mg, 10.4 μmol), sodium
ascorbate (4.4 mg, 22.2 μmol) and 0.5 mL H2O were then
added. The mixture was heated at 80 °C by microwave
irradiation (150 W) for 60 min. When the reaction was com-
pleted (checked via TLC, eluent: CH2Cl2–CH3OH 94 : 6), it was
quenched by addition of water (15 mL) and extracted with
AcOEt (5 × 15 mL). The combined organic layers were dried
over anhydrous Na2SO4, filtered and the solvent removed
in vacuo. The crude was purified by flash chromatography
(elution in gradient: CH2Cl2–CH3OH 96 : 4→95 : 5) giving
product 15 as a yellow oil. Yield: 57%. 1H NMR (300 MHz,
CDCl3): δ (ppm) 7.46 (bs, 10H, ArH); 7.40 (s, 5H, H5 triazole);
6.83 (bs, 5H, C(O)NH); 5.33 (d, 5H, J = 3.3 Hz, H4′); 5.17 (t, 5H,
J = 9.3 Hz, H3); 5.09 (dd, 5H, J1′–2′ = 7.9 Hz, J2′–3′ = 10.4 Hz,
H2′); 4.93 (dd, 5H, J2′–3′ = 10.4 Hz, J3′–4′ = 3.3 Hz, H3′); 4.86 (dd,
5H, J2–3 = 9.3 Hz, J1–2 = 8.1 Hz, H2); 4.50–4.38 (m, 25H, H1′,
H1, H6a, OCH2CH2-triazole); 4.15–4.00 (m, 15H, H6b, H6a′,
H6b′); 3.90–3.71 (m, 35H, H5′, H4, β-COCHa, ArCH2Ar,
OCH2CH2-triazole); 3.65–3.47 (m, 105H, OCH2, H5, C(O)-
NHCH2); 3.42 (m, 5H, β-COCHb); 3.21 (s, 15H, ArOCH3); 2.65
(t, 10H, J = 7.7 Hz, triazole-CH2CH2CH2); 2.12 (s, 15H, Ac); 2.09
(s, 15H, Ac); 2.04–1.98 (m, 60H, Ac); 1.94 (s, 15H, Ac);
1.65–1.55 (m, 10H, triazole-CH2CH2CH2); 1.55–1.44 (m, 10H,
β-COCH2CH2); 1.39–1.15 (m, 50H, CH2 aliphatic chain). 13C
NMR (100 MHz, CDCl3): δ ppm 170.4, 170.3, 170.2, 170.1,
169.8, 169.6, 169.1 (Ac); 167.3 (C(O)NH); 159.2 (Ar-ipso); 148.2
(C4 triazole); 134.2 (Ar-ortho); 129.9 (Ar-para); 128.2 (Ar-meta);
121.7 (C5 triazole); 101.1 (C1′); 100.6 (C1); 76.3 (C4); 72.8 (C3);
72.5 (C5); 71.7 (C2); 71.0 (C3′); 70.6 (C5′); 70.5 (OCH2); 70.2
(β-COCH2); 69.8 (OCH2); 69.6 (OCH2CH2-triazole); 69.1 (C2′);
66.6 (C4′); 62.1 (C6); 60.8 (C6′); 60.7 (ArOCH3); 50.0 (OCH2CH2-
triazole); 39.7 (C(O)NHCH2); 31.0 (ArCH2Ar); 29.5, 29.3, 25.8,
25.7 (CH2 aliphatic chain); 20.9, 20.8, 20.6, 20.5 (CH3C(O)).
HR-ESI-MS(+): m/z 1571.9445 [100% (M + 4Na)4+] calcd: 1571.940.
Galactosylcalix[5]arene (16)
The peracetylated-galactosylcalix[5]arene 14 (45.0 mg, 9.46 μmol)
was dissolved in 5 mL of CH3OH, drops of a freshly prepared
MeONa in methanol solution were added till pH 8–9. The
mixture was stirred at room temperature for 4 h. The progress
of the reaction was monitored via ESI-MS analysis. Amberlite
resin IR 120/H+ was subsequently added to quench the reac-
tion, and the mixture was gently stirred for 30 min. until
neutral pH was reached. The resin was then filtered oﬀ and
the solvent removed under vacuum to give pure product 16 as
a yellow oil. Yield. 90%. 1H NMR (300 MHz, CD3OD): δ (ppm)
8.23 (bs, 5H, C(O)NH); 7.77 (s, 5H, H5 triazole); 7.61 (s, 10H,
ArH); 4.51 (t, 10H, J = 5.0 Hz, OCH2CH2-triazole); 4.20 (d, 5H,
J = 7.1 Hz, H1); 3.94 (bs, 10H, ArCH2Ar); 3.92–3.80 (m, 20H, H4,
β-COCHa, OCH2CH2-triazole); 7.77–7.69 (m, 10H, H6a, H6b);
3.66–3.40 (m, 120H, β-COCHb, H2, H3, H5, OCH2, C(O)-
NHCH2); 3.29 (s, 15H, OCH3); 2.67 (t, 10H, J = 7.6 Hz, triazole-
CH2CH2CH2); 1.72–1.53 (m, 20H, triazole-CH2CH2CH2,
β-COCH2CH2); 1.44–1.24 (m, 50H, CH2 aliphatic chain). 13C
NMR (75 MHz, CD3OD): δ ppm 169.6 (C(O)NH); 160.9 (Ar-ipso);
149.0 (C4 triazole); 135.8 (Ar-ortho); 130.7 (Ar-para); 129.7 (Ar-
meta); 124.0 (C5 triazole); 105.0 (C1); 76.6, 75.1, 72.6 (C2, C3,
C5); 71.5, 71.4, 71.3, 70.8, 70.6, 70.4, 70.3 (OCH2, β-COCH2,
C4); 62.5 (C6); 61.5 (ArOCH3); 51.3 (OCH2CH2-triazole); 41.0
(C(O)NHCH2); 32.0 (ArCH2Ar); 30.8, 30.6, 30.5, 30.4, 30.3, 27.1
(CH2 aliphatic chain); 26.3 (triazole-CH2CH2CH2). HR-ESI-MS
(+): m/z 1305.0569 [100% (M + 3H)3+] calcd: 1305.0601
Lactosylcalix[5]arene (17)
The peracetylated-lactosylcalix[5]arene 15 (42.0 mg, 6.8 μmol)
was dissolved in 5 mL of CH3OH, and drops of a freshly pre-
pared methanol solution of MeONa were added till pH 8–9.
The mixture was stirred at room temperature for 18 h. The pro-
gress of the reaction was monitored via ESI-MS analysis.
Amberlite resin IR 120/H+ was subsequently added for quench-
ing, and the mixture was gently stirred for 30 min till neutral
pH. The resin was then filtered oﬀ and the solvent removed
under vacuum to give pure product 17 as a yellow oil. Yield:
72%. 1H NMR (300 MHz, CD3OD): δ (ppm) 7.79 (s, 5H, H5 tria-
zole); 7.60 (s, 10H, ArH); 4.51 (t, 10H, J = 5.0 Hz, OCH2CH2-tria-
zole); 4.35 (d, 5H, J = 7.3 Hz, H1′); 4.26 (d, 5H, J = 7.8 Hz, H1);
3.93 (bs, 10H, ArCH2Ar); 3.90–3.65 (m, 40H, H4′, H6ab′, H6ab,
Glc β-COCHa, OCH2CH2-triazole); 3.65–3.35 (m, 135H, H3, H4,
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H5, H2′, H3′, H5′, Glc β-COCHb, OCH2, C(O)NHCH2); 3.28 (s,
15H, OCH3); 3.23 (t, 5H, J = 8.4 Hz, H2); 2.66 (t, 10H, J = 7.6
Hz, triazole-CH2CH2CH2); 1.69–1.53 (m, 20H, CH2 aliphatic
chain); 1.42–1.23 (m, 50H, CH2 aliphatic chain).
13C NMR
(75 MHz, CD3OD): δ ppm 169.6 (C(O)NH); 160.9 (Ar-ipso);
148.8 (C4 triazole); 135.7 (Ar-ortho); 130.7 (Ar-para); 129.7 (Ar-
meta); 124.2 (C5 triazole); 105.1 (C1′); 104.2 (C1); 80.7 (C4);
77.0, 76.5, 76.4, 74.8, 74.7, 72.5 (C2, C3, C5, C2′, C3′, C5′); 71.5,
71.4, 71.3, 70.9, 70.6, 70.4 (OCH2, β-COCH2,); 70.3 (C4′); 62.5,
61.9 (C6, C6′); 61.5 (ArOCH3); 51.4 (OCH2CH2-triazole); 41.0
(C(O)NHCH2); 32.0 (ArCH2Ar); 30.8, 30.6, 30.5, 30.4, 30.2, 27.1
(CH2 aliphatic chain); 26.2 (triazole-CH2CH2CH2). HR-ESI-MS
(+) m/z: 1575.1475 [100% (M + 3H)3+] calcd: 1575.1481.
17-Azide-3,6,9,12,15-pentaoxaheptadecane-1-aminocarbonyl-p-
methoxybenzene (19)
Oxalyl chloride (1.5 mL, 16.0 mmol) was added to a solution of
4-methoxybenzoic acid (0.30 g, 2.0 mmol) in 15 mL of dry
CH2Cl2 and the mixture was stirred at room temperature under
N2 for 18 h. The solvent was then removed under vacuum and
the residue dissolved again in 5 mL of dry CH2Cl2. This solu-
tion was added dropwise to a round bottomed flask containing
the azidoamine compound 7 (0.91 g, 3.0 mmol) and NEt3
(0.5 mL, 3.0 mmol) in 10 mL of dry CH2Cl2. The mixture was
let to react for 20 h at room temperature under an N2 atmos-
phere. The reaction was monitored via TLC (eluent: AcOEt). A
1 M HCl solution (20 mL) was then added to quench the reac-
tion, and the product extracted with CH2Cl2 (2 × 20 mL). The
combined organic phases were washed with NaHCO3 saturated
aqueous solution (15 mL), brine (15 mL), water (15 mL), dried
over anhydrous Na2SO4, filtered and the solvent evaporated
under reduced pressure. The crude was purified by flash
chromatography (eluent: AcOEt–acetone 9 : 1). Product 19 was
obtained pure as a yellow oil. Yield: 20%. 1H NMR (300 MHz,
CDCl3): δ (ppm) 7.74 (d, 2H, J = 8.9 Hz, Ar-meta); 6.87 (d, 2H,
J = 8.9 Hz, Ar-ortho); 6.78 (bs, 1H, C(O)NH); 3.80 (s, 3H, OCH3);
3.65–3.54 (m, 22H, OCH2, C(O)NHCH2); 3.32 (t, 2H, J = 5.0 Hz,
CH2N3).
13C NMR (75 MHz, CDCl3): δ ppm 167.0 (Ac); 162.0
(Ar-ipso); 128.8 (Ar-meta); 126.9 (Ar-para); 113.6 (Ar-ortho); 70.6,
70.5, 70.2, 70.0, 69.9 (OCH2); 55.4 (OCH3); 50.6 (CH2N3); 39.7
(C(O)NHCH2). ESI-MS(+) m/z: 463.0 [100% (M + Na)
+]; 435.0
[60% (M − N2 + Na)+].
GM1os-monomer (20)
Starting from compounds 19 and 9, following the same pro-
cedure as for compound 1, and using reversed phase column
chromatography for the purification (gradient MeOH–H2O–
AcOH), monomer 20 was obtained as a white solid in 49%
yield. 1H NMR (400 MHz, D2O): δ (ppm) 7.81 (3H, m, triazole,
Ar), 6.98 (2H, d, J = 8.4 Hz, Ar), 4.71 (1H, s, H1-GalNAc), 4.39
(1H, d, J = 8.4 Hz, H1-Gal′), 4.42 (1H, m, H1-Gal), 4.38 (1H, m),
4.31, (1H, d, J = 8.2 Hz, H1-Glc), 4.05–4.01 (3H, m), 3.93 (1H,
m, H2-GalNAc), 3.75–3.40 (21H, m) , 3.60–3.47 (16H, m),
3.36–3.28 (14H, m), 3.25 (1H, m, H2-Gal), 3.18 (1H, m, H2-
Glc), 3.10 (2H, s), 2.54 (1H, m, H3a-Neu5Ac), 2.35 (2H, m, CH2-
triazole), 1.92 (3H, s, NHC(O)CH3-Neu5Ac), 1.85 (3H, s, NHC-
(O)CH3-GalNAc), 1.75 (1H, m, H3b-Neu5Ac), 1.40 (4H, m), 1.11
(2H, m, Glc β-COCH2CH2), 1.03 (8H, m, –CH2CH2CH2–); 13C
NMR (75 MHz, D2O): δ (ppm) 174.8, 174.5, 173.9, 168.5, 159.2,
128.4 (2 × CH Ar), 123.1 (C5 triazole), 113.2 (2 × CH Ar) 104.6
(C1-Gal′), 102.7 (C1-Gal), 102.4 (C1-GalNAc), 102.0 (C1-Glc),
101.5 (C2-Neu5Ac), 80.2 (C3-GalNAc), 78.5 (C4-Glc), 77.0 (C4-
Gal), 74.7, 74.6, 74.4, 74.2, 74.1, 74.0, 73.9 (C2 Glc), 72.6 (C3
Gal′), 72.3, 72.1 (C2-Gal′), 70.6 (Glc β-COCH2), 70.4 (C2-Gal),
70.4–68.5 (–OCH2–), 68.4 (C4-GalNAc), 67.8, 62.7, 60.9, 60.8,
60.4, 60.0, 51.4, 51.0 (C2 GalNAc), 49.8, 39.5, 36.7, 28.8–28.3
(CH2CH2CH2), 25.0 (Glc β-COCH2CH2), 24.5 (CH2-triazole),
22.5 (NHC(O)CH3-GalNAc), 21.9 (NH(O)CH3-Neu5Ac); HR-ESI-
MS(−) m/z: 1587.7009 [100% (M − H)−] calcd: 1587.7034.
CTB5 inhibition assays
Each well of a 96-well microtiter plate was coated with a 100 μL
native GM1 solution (1.3 μM in ethanol) after which the
solvent was evaporated. Unattached GM1 was removed by
washing with PBS (3 × 450 μL), the remaining free binding
sites were blocked by incubation with 100 μL of a 1% (w/v) BSA
solution in PBS for 30 min at 37 °C. Detection limits were
determined by placing a CT-horseradish peroxidase conjugate
(CT-HRP), without inhibitor, on the plate, which gives the
highest response, and the lowest response was determined by
the optical density of the blank, i.e. the native GM1-coated well
with all components except the inhibitor and the toxin. These
two values represent the minimum and the maximum values
of optical density, 0% and 100% of binding of the CT to the
GM1-coating of the wells. Subsequently, the wells were washed
with PBS (3 × 450 μL). In separate vials, a logarithmic serial
dilution was performed that started from 2.0 mM of 150 μL
saccharide-calixarenes in 0.1% BSA and 0.05% Tween-20 in
PBS. Next, each vial was mixed and incubated with 150 μL of a
50 ng mL−1 CTB-HRP solution in the same buﬀer. This gave
an initial inhibitor concentration of 1.0 mM. In the case of
potent inhibitors, based on the logarithmic experiments, a
more accurate, serial dilution of a factor two was performed
around the expected IC50-values. The inhibitor–toxin mixtures
were incubated at room temperature for 2 h and then trans-
ferred to the coated wells. After 30 min of incubation at room
temperature, unbound CTB-HRP-calixarene complexes were
removed from the wells by washing with 0.1% BSA, 0.05%
Tween-20 in PBS (3 × 500 μL). 100 μL of a freshly prepared OPD
solution (25 mg OPD·2HCl, 7.5 mL 0.1 M citric acid, 7.5 mL
0.1 M sodium citrate and 6 μL of a 30% H2O2 solution, pH was
adjusted to 6.0 with NaOH) was added to each well and
allowed to react with HRP in the absence of light, at room
temperature, for 15 minutes. The oxidation reaction was
quenched by addition of 50 μL 1 M H2SO4. Within 5 min, the
absorbance was measured at 490 nm.
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